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Ovarian cancer is a malignancy of the female ova-
ries and one of the main causes of death in the
world besides cervical cancer. In the field of gyne-
cologic cancer, a malignancy of the ovary is the big-
gest clinical challenge. But until now pathogenesis
or cause of ovarian cancer is not yet clear, precau-
tions that can be done and treatment of ovarian
cancer has not been satisfactory. Often patients
come in the advance stage so that the operative
treatment or chemotherapy can not give much
hope to the patient.
Major cause of ovarian cancer is still a matter of
debate, but there are some risk factors that have
been widely studied and is thought to be a trigger
of the ovarian cancer include genetic factors, age,
parity, race, and family history of breast cancer and
ovarian cancer.1-3 At the biomolecular level genetic
Abstract
Objective: To determine the difference of HER2/neu expression in
benign, borderline and malignant epithelial ovarian tumor.
Method: An analytic cross-sectional study was performed on 49
samples of epithelial ovarian cases which were divided into three
groups: twelve cases of benign epithelial ovarian tumor, 9 cases of
borderline epithelial ovarian tumor and 28 cases of malignant epi-
thelial ovarian tumor. Paraffin embedded tissue samples was cut,
stained with HER2/neu imunohistochemistry and examined in Pa-
thology Laboratory at Sanglah Hospital. The other data was collected
from medical record samples. The data was analysed using One Way
Anova test and Chi-square test with level of confidence α = 0.05.
Result: There were 13 cases (46.43%) of the HER2/neu over ex-
pression in malignant epithelial ovarian tumors, 2 cases (22.22%) of
the HER2/neu over expression in borderline epithelial ovarian tu-
mors and 1 case (9.09%) of the HER2/neu over expression in benign
epithelial ovarian tumors. With p = 0.048 (p < 0.05), there are differ-
entiation of HER2/neu expression in benign, borderline and malig-
nant epithelial ovarian tumors.
Conclusion: In this study HER2/neu expression was different be-
tween benign, borderline and malignant epithelial ovarian tumors.
[Indones J Obstet Gynecol 2014; 2-1: 46-49]
Keywords: benign epithelial ovarian tumor, borderline epithelial
ovarian tumor, HER2/neu, malignant epithelial ovarian tumor, ova-
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Abstrak
Tujuan: Untuk mengetahui adanya perbedaan ekspresi HER2/neu
pada tumor ovarium epitelial jinak, borderline dan ganas.
Metode: Merupakan uji potong lintang analitik. Jumlah sampel ada-
lah sebesar 49 sampel di mana 12 kasus dengan tumor ovarium
epitelial tipe jinak, 9 kasus dengan tumor ovarium epitelial tipe bor-
derline dan 28 kasus dengan tumor ovarium epitelial tipe ganas. Blok
parafin sampel dipotong ulang, dilakukan pengecatan imunohisto-
kimia HER2/neu dan diperiksa ekspresi HER2/neu pada Laborato-
rium Patologi Anatomi Rumah Sakit Sanglah. Sedangkan data lain
penelitian diperoleh dari rekam medis sampel. Dari data yang ter-
kumpul dilakukan uji One Way Anova untuk karakteristik sampel, ke-
mudian dilakukan analisa data dengan uji Chi-square dengan tingkat
kemaknaan α = 0,05.
Hasil: Overekspresi HER2/neu pada tumor ovarium epitelial tipe ga-
nas adalah sebanyak 13 kasus (46,43%) dibandingkan dengan over
ekspresi HER2/neu pada tumor ovarium epitelial tipe borderline yang
hanya sebanyak 2 kasus (22,22%) dan tipe jinak yang hanya sebanyak
1 kasus (9,09%). Dengan nilai p = 0,048 (p < 0,05) maka terdapat per-
bedaan ekspresi HER2/neu pada tumor ovarium epitelial tipe jinak,
borderline dan ganas.
Kesimpulan: Berdasarkan hasil penelitian didapatkan bahwa terda-
pat perbedaan ekspresi HER2/neu pada tumor ovarium epitelial tipe
jinak, borderline dan ganas.
[Maj Obstet Ginekol Indones 2014; 2-1: 46-49]
Kata kunci: HER2/neu, kanker ovarium, tumor ovarium epitelial tipe
jinak, tumor ovarium epitelial tipe borderline, tumor ovarium epitelial
tipe ganas.
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mutations occur, one of which occurred amplifica-
tion of oncogenes that results in over expression of
some proteins. Human Epidermal Growth Factor
Receptor 2 (HER2) oncogene, which is also known
as HER2/neu, ErbB2 or c-ErbB2, presumably plays
an important role in the carcinogenesis process.
HER2/neu is a receptor on the cell surface that have
the same structure as the Epidermal Growth Factor
Receptor (EGFR), is located on chromosome 17q21
which encodes a trans membrane glycoprotein via
tyrosine kinase activity. Her2/neu bonding with li-
gand will trigger phosphorilation and dimerization
process so that the signal transduction mechanism
of activation can be submitted through Phosphoi-
nositides 3-kinase (PI3K) and mitogen-activated
protein kinase (MAPK) to trigger cancer cell prolife-
ration and blood vessel formation (angiogenesis).4
In breast tumors, over expression of HER2/neu
around 25% of all breast cancer cases. HER2/neu
has been shown to play a role in carcinogenesis and
prognosis of breast carcinoma and has also develo-
ped a method for HER-2/neu targeted therapy.
On ovarian tumors, HER2/neu over expression
varies between 9% to 32%. However, the role of
HER2/neu in ovarian cancer has not been widely
studied. HER-2/neu role in carcinogenesis and
prognosis of ovarian cancer is still controversial.5
By knowing the HER2/neu expression in ovarian
tumors might be expected to reveal the role of
HER2/neu in ovarian tumor in carcinogenesis,
prognostic and therapeutic targets in the future. 
METHOD
This study uses cross sectional analytic study. Sam-
ple is drawn from populations by consecutive sam-
pling. Subjects were patients of epithelial ovarian
tumors in Sanglah Hospital from January 2011 to
April 2012, who met the inclusion criteria. The in-
clusion criteria for the study were as follows: la-
parotomy surgery at Sanglah, histopathologic exa-
mination in Anatomical Pathology Laboratory Sang-
lah, medical records of patients in the Medical
Record Sanglah Installation and paraffin blocks of
patients are still there and in good condition for
HER2 immunohistochemistry examination/neu.
This study was conducted from January 2012 to
December 2012 and obtained reasonable popula-
tions of epithelial ovarian tumors of 63 patients, of
which 9 patients did not meet the inclusion criteria
and 5 patients dropped out. Thus, the number of
patients who underwent the study until the end
were 49 patients with epithelial ovarian tumors.
Then 49 samples of paraffin blocks and secondary
data were collected from the Pathology Anatomy
and Obstetrics and Gynecology Department, Faculty
of Medicine, Udayana University/Sanglah Hospital.
The samples consisted of 12 cases with benign epi-
thelial ovarian tumors, 9 cases with borderline epi-
thelial ovarian tumors and 28 cases with malignant
epithelial ovarian tumors. HER2/neu immunohisto-
chemistry examination was performed on the sam-
ples that have been collected was done, then exam-
ined by a pathologist at Pathology Anatomy Depart-
ment of Sanglah Hospital to determine the ex-
pression of HER2/neu. The data collected were
processed using the computer program SPSS for
Windows version 17.0.
RESULT
In this cross sectional analytic study characteristics
diference sample test was done between groups
with One Way Anova test for maternal age and pa-
rity variables. Results of the analysis are presented
in Table 1 below.
Table 1. The Mean Age and Parity Distribution of Epi-






Age 39.67±12.22 48.11±12.90 46.46±10.43 0.685
Parity 1.92±1.31 2.56±1.74 1.79±1.16 0.302
In Table 1, it is indicated that between benign,
borderline and malignant group of epithelial ova-
rian tumors, did not differ in age, with p = 0.685 (p
> 0.05), as well as the parity variables with p =
0.302 (p > 0.05).
Chi-Square test was used to determine differen-
ce in HER2/neu expression between benign, bor-
derline and malignant group of epithelial ovarian
tumors. Significance of analysis results are presen-
ted in Table 2.
In Table 2 indicated that HER2/neu over expres-
sion in epithelial ovarian tumors are malignant type
were 13 cases (46.43%), borderline type which
only 2 cases (22.22%) and benign type that only 1
case (9, 09%). With p = 0.048 (p <0.05) then there
is a difference in HER2/neu expression in benign,
borderline and malignant epithelial ovarian tumors.
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DISCUSSION
In this study, we examined HER2/neu immunohis-
tochemistry in 49 samples of epithelial ovarian tu-
mors. The samples consisted of 12 cases with be-
nign epithelial ovarian tumors, 9 cases with bor-
derline epithelial ovarian tumors and 28 cases with
malignant epithelial ovarian tumors.
The mean age in the group of benign epithelial
ovarian tumors are 39.67 ± 12.22 years, borderline
was 48.11 ± 12.90 years and malignant was 46.46
± 10.43 years, which was not statistically signifi-
cant, p = 0.685 (p> 0,05). Similarly, the mean parity
in the group of benign epithelial ovarian tumors
was 1.92 ± 1.31, borderline was 1.74 ± 2.56 and
malignat was 1.79 ± 1.16, which was also statisti-
cally not significant, p = 0.302 (p> 0,05). This result
is similar according to a multicentre study of 320
patients in France, where the HER2/neu status has
no significant impact on the patient’s age or parity.6
After examination of the HER2/neu immunohis-
tochemistry showed that the HER2/neu over ex-
pression in malignant epithelial ovarian tumors in
this study was 46.43% (13 of 28 cases), borderline
epithelial ovarian tumors was only 28.57 % (2 of
9 cases), and benign epithelial ovarian tumors was
only 9.09% (1 of 12 cases).
A clinical study on the prevalence and prognosis
relationships HER2/neu over expression in epi-
thelial ovarian cancer cases, showed HER2/neu
over expression by 13.9% (27 of 194 cases) of epi-
thelial ovarian cancer. It was concluded in this
study that over expression of HER2/neu associated
increase in ovarian cancer progression and death.7
An article review of previous studies since 1989
show that HER2/neu over expression in malignant
epithelial ovarian tumors ranged from 1.8 to 76%.
In the article it was also found that HER2/neu over
expression in borderline epithelial ovarian tumors
ranged from 10% to 66%. HER2/neu over expres-
sion percentage range is very wide it is associated
with many factors, such as sample size, type of
monoclonal antibody used, the intensity of stain-
ing, the tissue examined and the definition of
HER2/neu over expression.8
A study to determine the prognostic value and
HER2/neu over expression in 44 cases of benign
epithelial ovarian tumors and 124 cases of epi-
thelial ovarian cancer, showed that there was no
over expression in benign ovarian tumors and
HER2/neu over expression in epithelial ovarian
cancer was 24.2%. It is associated with advanced
stage ovarian cancer, clear cell and undifferenti-
ated type and suboptimal surgery. HER2/neu over
expression simultaneously associated with ovarian
cancer prognosis is worse.9
A multicenter study in France involving 320 pa-
tients to investigate the HER2/neu status in ova-
rian carcinoma by immunohistochemistry was
12.8% (41 cases). They also do a review on the
previous choice studies since 1994, found the num-
ber of HER2/neu over expression ranged from 8%
to 66%. Several explanations could explain the
wide variation among others: the difference detec-
tion methods (immunohistochemistry, FISH (fluo-
rescence in-situ hybridization) and chromogenic in
situ hybridization), differences in materials and
technique variations CPI (CB-11, Hercep Test or
non-commercial antibody). This study is the first
large-scale multicenter ever done.6
While the study of HER2/neu over expression in
benign serous epithelial ovarian tumor benign
found that HER2/neu over expression was 12.5%
(2 cases out of 15 samples).10 However, in previous
studies on benign epithelial ovarian tumors, HER2/
neu over expression was not obtained.11,12
The main result in this study is that HER2/neu
expression was different between benign, border-
line and malignant epithelial ovarian tumors, with
p = 0.048 (p < 0.05). Thus, HER2/neu in ovarian
cancer is interesting to study due to its potential




Malignant group 13 15
Epithelial Ovarian Tumor Borderline group 2 7 6.089 0.048
Benign group 1 11
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role in the pathophysiology, prognosis factors and
targeted pharmacotherapy.8 However, these re-
sults still could not determine HER2/neu over ex-
pression as the cause of ovarian cancer because the
relationship of HER2/neu over expression and
ovarian cancer was inconsistent in previous stu-
dies. This study also could not determine the effect
of Transtuzumab use as a therapeutic option in pa-
tients with ovarian cancer with HER2/neu over ex-
pression, because clinical trials should be per-
formed in order to provide adequate evidence.
While the role of HER2/neu over expression as a
prognostic factor still requires studies that com-
pare between HER2/neu over expression with
prognostic factors in ovarian cancer, such as stage,
histological type or differentiation of ovarian can-
cer cells.
The weakness of this study is that cross-sec-
tional analytical method can only determine whe-
ther there is a difference between a group and can
not know the difference or the strength of the re-
lationship between the study variables. Then this
study used secondary data where data was incom-
plete, especially when looking for family history
data with breast cancer and ovarian cancer. So that
a family history of breast cancer and ovarian can-
cer as a risk factor for ovarian cancer can not be
analyzed.
CONCLUSIONS
HER2/neu expression was different between be-
nign, borderline and malignant epithelial ovarian
tumors.
REFFERENCE
1. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial Ova-
rian Cancer. In: Hoskins WJ, Perez CA, Young RC. Principles
and Practice of Gynecologic Oncology, 4th Edition Lippincott
Williams and Wilkins. 2005: 896-987.
2. Schorge JO. Epithelial Ovarian Cancer. In: Schorge JO, Schaf-
fer JI, Halvorson LM et al. Williams Gynecology. The McGraw
Hill Companies. 2008.
3. Fauzan R. Gambaran faktor penggunaan kontrasepsi ter-
hadap angka kejadian kanker ovarium di RSUPN Dr. Cipto
Mangunkusumo Jakarta berdasarkan pemeriksaan histopa-
tologik tahun 2003-2007 (tesis). Jakarta: Universitas Indo-
nesia. 2009.
4. Mayr D, Kanitz V, Ammann G, Engel J, Burges ALohrs U,
Diebold. HER2/neu gene amplification in ovarian tumors: a
comprehensive immunohistochemical and FISH analysis on
tissue microarrays, Histopathology. 2006; 48: 149-56.
5. Tai W, Mahato R, Cheng K. The role of HER2 in cancer the-
rapy and targeted drug delivery. J Controlled Released,
2010; 146: 264-75.
6. Tuefferd M, Couturier J, Penault-Liorca F, Vincent-Salomon
A, Broet P, et al. HER2 Status in Ovarian Carcinoma: A Mul-
ticenter GINECO Study of 320 patients. PloS ONE 2007.
2(11): e1138. doi: 10.1371/journal.pone.0001138
7. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A,
Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu On-
coprotein Overexpression in Epithelial Ovarian Cancer:
Evaluation of its Prevalence and Prognostic Significance
Clinical Study. Oncology 2005; 68: 154-61.
8. Serrano-Olvera A, Duenas-Gonzales A, Gallardo-Rincon D,
Candelaria M, Garza-Salazar J. Prognostic, predictive and
therapeutic implications of HER2 in invasive epithelial ova-
rian cancer. Cancer Treatment Review. 2006; 32: 180-90.
9. Martin C, Laiz F, Santos G, Mena R, Aragon V. Overexpres-
sion and Prognostic Value of p53 and HER2/neu proteins
in benign ovarian tissue and in ovarian cancer. Med Clin
(Barc) 2007; 128(1): 1-6.
10. Marinas MC, Mogos G, Ciurea R, Mogos DG. EGFR, HER2/
neu and Ki67 immunoexpression in serous ovarian tumors.
Rom J Morphol Embryol, 2012; 53(3): 563-7.
11. Ito K, Sasano H, Ozawa N, Sato S, Silverberg SG, Yajima A.
Immunolocalization of epidermal growth factor receptor
and c-erbB-2 oncogene product in human ovarian carci-
noma. Int J Gynecol Pathol 1992; 11(4): 253-7.
12. Harlozinska A, Bar JK, Sobanska E, Goluda M. Epidermal
growth factor receptor and c-erbB-2 oncoproteins in tissue
and tumor effusion cells of histopatological different ova-
rian neoplasms. Tumour Biol 1998; 19(5): 364-73.
Vol 2, No 1
January 2014 Differences of HER2/Neu expression  49
